Money from Sick People Part III: Why is U.S. drug pricing policy designed to exploit patients?
Ben LinkBrand drugs, List prices, Rebates, WAC, Insulin, Lantus, PBM, Humalog, 340B, Medicaid, McKesson, pharmacy
How money from sick people works, Part II: The 340B story
Ben LinkBrand drugs, List prices, Rebates, WAC, Insulin, Lantus, PBM, Humalog, CVS, 340B, Medicaid, McKesson, pharmacy
The unseasonably warm January drug price changes
Ben LinkNADAC, Medicaid, Generic, Brand drugs, List prices, Rebates, WAC, MDRP, American Rescue Plan Act, Advair, Asmanex, Symbicort, Apidra, Lantus, Levemir, Novolog, Victoza, Nucynta, Oxycontin, Butrans, Edarbi, Edarbyclor, Eliquis, Femring, Ferripox, Horizant, Verkazia, Wellbutrin, venlafaxine, lamotrigine, varenicline, atomoxetine
New year, new drug prices ... but is it a brave new pricing world?
New report reveals how PBMs distort and undermine specialty drug pricing guarantees
Contextualizing Drug Prices (Again)
Welcoming a New Year with new drug prices
Ben LinkMDRP, Rebates, Medicaid, WAC, List prices, Inflation, CPI, Inflation Reduction Act, Imbruvica, Farxiga, Jardiance, Biktarvy, Triumeq, Vyvanse, Price increases, Humira, Enbrel, Cosentyx, Norditropin, Otezla, Gilenya, Entresto, Uptravi, Promacta, Sabril
How low can you go? Newly launched dashboard explores 340B’s deeply discounted drug prices
New report digs into Medicare's $200 billion in gross drug expenditures
